Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Dec;81(8):1402–1409. doi: 10.1038/sj.bjc.6692231

Gain of chromosome arm 17q is associated with unfavourable prognosis in neuroblastoma, but does not involve mutations in the somatostatin receptor 2 (SSTR2) gene at 17q24

F Abel 1, K Ejeskär 1, P Kogner 2, T Martinsson 1
PMCID: PMC2362984  PMID: 10604740

Abstract

Deletion of chromosome arm 1p and amplification of the MYCN oncogene are well-recognized genetic alterations in neuroblastoma cells. Recently, another alteration has been reported; gain of the distal part of chromosome arm 17q. In this study 48 neuroblastoma tumours were successfully analysed for 17q status in relation to known genetic alterations. Chromosome 17 status was detected by fluorescence in situ hybridization (FISH). Thirty-one of the 48 neuroblastomas (65%) showed 17q gain, and this was significantly associated with poor prognosis. As previously reported, 17q gain was significantly associated with metastatic stage 4 neuroblastoma and more frequently detected than both deletion of chromosome arm 1p and MYCN amplification in tumours of all stages. 17q gain also showed a strong correlation to survival probability (P = 0.0009). However, the most significant correlation between 17q gain and survival probability was observed in children with low-stage tumours (stage 1, 2, 3 and 4S), with a survival probability of 100% at 5 years from diagnosis for children with tumours showing no 17q gain compared to 52.5% for those showing 17q gain (P = 0.0021). This suggests that 17q gain as a prognostic factor plays a more crucial role in low-stage tumours. Expression of the somatostatin receptor 2 (SSTR2), localized in chromosome region 17q24, has in previous studies been shown to be positively related to survival in neuroblastoma. A point mutation in the SSTR2 gene has earlier been reported in a human small-cell lung cancer. In this study, mutation screening of the SSTR2 gene in 43 neuroblastoma tumours was carried out with polymerase chain reaction-based single-stranded conformation polymorphism/heteroduplex (SSCP/HD) and DNA sequencing, and none of the tumours showed any aberrations in the SSTR2 gene. These data suggest that mutations in the SSTR2 gene are uncommon in neuroblastoma tumours and do not correlate with either the 17q gain often seen or the reason some tumours do not express SSTR2 receptors. Overall, this study indicates that gain of chromosome arm 17q is the most frequently occurring genetic alteration, and that it is associated with established prognostic factors. © 1999 Cancer Research Campaign

Keywords: 17q, SSTR2, neuroblastoma

Full Text

The Full Text of this article is available as a PDF (353.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ambros P. F., Ambros I. M., Strehl S., Bauer S., Luegmayr A., Kovar H., Ladenstein R., Fink F. M., Horcher E., Printz G. Regression and progression in neuroblastoma. Does genetics predict tumour behaviour? Eur J Cancer. 1995;31A(4):510–515. doi: 10.1016/0959-8049(95)00044-j. [DOI] [PubMed] [Google Scholar]
  2. Bell G. I., Yasuda K., Kong H., Law S. F., Raynor K., Reisine T. Molecular biology of somatostatin receptors. Ciba Found Symp. 1995;190:65–88. doi: 10.1002/9780470514733.ch5. [DOI] [PubMed] [Google Scholar]
  3. Brodeur G. M., Pritchard J., Berthold F., Carlsen N. L., Castel V., Castelberry R. P., De Bernardi B., Evans A. E., Favrot M., Hedborg F. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993 Aug;11(8):1466–1477. doi: 10.1200/JCO.1993.11.8.1466. [DOI] [PubMed] [Google Scholar]
  4. Caron H., van Sluis P., de Kraker J., Bökkerink J., Egeler M., Laureys G., Slater R., Westerveld A., Voûte P. A., Versteeg R. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med. 1996 Jan 25;334(4):225–230. doi: 10.1056/NEJM199601253340404. [DOI] [PubMed] [Google Scholar]
  5. Caron H., van Sluis P., van Roy N., de Kraker J., Speleman F., Voûte P. A., Westerveld A., Slater R., Versteeg R. Recurrent 1;17 translocations in human neuroblastoma reveal nonhomologous mitotic recombination during the S/G2 phase as a novel mechanism for loss of heterozygosity. Am J Hum Genet. 1994 Aug;55(2):341–347. [PMC free article] [PubMed] [Google Scholar]
  6. Dib C., Fauré S., Fizames C., Samson D., Drouot N., Vignal A., Millasseau P., Marc S., Hazan J., Seboun E. A comprehensive genetic map of the human genome based on 5,264 microsatellites. Nature. 1996 Mar 14;380(6570):152–154. doi: 10.1038/380152a0. [DOI] [PubMed] [Google Scholar]
  7. Gale G. B., D'Angio G. J., Uri A., Chatten J., Koop C. E. Cancer in neonates: the experience at the Children's Hospital of Philadelphia. Pediatrics. 1982 Sep;70(3):409–413. [PubMed] [Google Scholar]
  8. Kogner P., Borgström P., Bjellerup P., Schilling F. H., Refai E., Jonsson C., Dominici C., Wassberg E., Bihl H., Jacobsson H. Somatostatin in neuroblastoma and ganglioneuroma. Eur J Cancer. 1997 Oct;33(12):2084–2089. doi: 10.1016/s0959-8049(97)00212-8. [DOI] [PubMed] [Google Scholar]
  9. Lastowska M., Cotterill S., Pearson A. D., Roberts P., McGuckin A., Lewis I., Bown N. Gain of chromosome arm 17q predicts unfavourable outcome in neuroblastoma patients. U.K. Children's Cancer Study Group and the U.K. Cancer Cytogenetics Group. Eur J Cancer. 1997 Sep;33(10):1627–1633. doi: 10.1016/s0959-8049(97)00282-7. [DOI] [PubMed] [Google Scholar]
  10. Lastowska M., Roberts P., Pearson A. D., Lewis I., Wolstenholme J., Bown N. Promiscuous translocations of chromosome arm 17q in human neuroblastomas. Genes Chromosomes Cancer. 1997 Jul;19(3):143–149. [PubMed] [Google Scholar]
  11. Lastowska M., Van Roy N., Bown N., Speleman F., Lunec J., Strachan T., Pearson A. D., Jackson M. S. Molecular cytogenetic delineation of 17q translocation breakpoints in neuroblastoma cell lines. Genes Chromosomes Cancer. 1998 Oct;23(2):116–122. doi: 10.1002/(sici)1098-2264(199810)23:2<116::aid-gcc4>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  12. Look A. T., Hayes F. A., Shuster J. J., Douglass E. C., Castleberry R. P., Bowman L. C., Smith E. I., Brodeur G. M. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol. 1991 Apr;9(4):581–591. doi: 10.1200/JCO.1991.9.4.581. [DOI] [PubMed] [Google Scholar]
  13. Martinsson T., Sjöberg R. M., Hallstensson K., Nordling M., Hedborg F., Kogner P. Delimitation of a critical tumour suppressor region at distal 1p in neuroblastoma tumours. Eur J Cancer. 1997 Oct;33(12):1997–2001. doi: 10.1016/s0959-8049(97)00278-5. [DOI] [PubMed] [Google Scholar]
  14. Martinsson T., Sjöberg R. M., Hedborg F., Kogner P. Deletion of chromosome 1p loci and microsatellite instability in neuroblastomas analyzed with short-tandem repeat polymorphisms. Cancer Res. 1995 Dec 1;55(23):5681–5686. [PubMed] [Google Scholar]
  15. Meddeb M., Danglot G., Chudoba I., Vénuat A. M., Bénard J., Avet-Loiseau H., Vasseur B., Le Paslier D., Terrier-Lacombe M. J., Hartmann O. Additional copies of a 25 Mb chromosomal region originating from 17q23.1-17qter are present in 90% of high-grade neuroblastomas. Genes Chromosomes Cancer. 1996 Nov;17(3):156–165. doi: 10.1002/(SICI)1098-2264(199611)17:3<156::AID-GCC3>3.0.CO;2-3. [DOI] [PubMed] [Google Scholar]
  16. Patel Y. C., Greenwood M. T., Panetta R., Demchyshyn L., Niznik H., Srikant C. B. The somatostatin receptor family. Life Sci. 1995;57(13):1249–1265. doi: 10.1016/0024-3205(95)02082-t. [DOI] [PubMed] [Google Scholar]
  17. Patel Y. C., Greenwood M., Kent G., Panetta R., Srikant C. B. Multiple gene transcripts of the somatostatin receptor SSTR2: tissue selective distribution and cAMP regulation. Biochem Biophys Res Commun. 1993 Apr 15;192(1):288–294. doi: 10.1006/bbrc.1993.1412. [DOI] [PubMed] [Google Scholar]
  18. Plantaz D., Mohapatra G., Matthay K. K., Pellarin M., Seeger R. C., Feuerstein B. G. Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization. Am J Pathol. 1997 Jan;150(1):81–89. [PMC free article] [PubMed] [Google Scholar]
  19. Seeger R. C., Brodeur G. M., Sather H., Dalton A., Siegel S. E., Wong K. Y., Hammond D. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med. 1985 Oct 31;313(18):1111–1116. doi: 10.1056/NEJM198510313131802. [DOI] [PubMed] [Google Scholar]
  20. Sestini R., Orlando C., Peri A., Tricarico C., Pazzagli M., Serio M., Pagani A., Bussolati G., Granchi S., Maggi M. Quantitation of somatostatin receptor type 2 gene expression in neuroblastoma cell lines and primary tumors using competitive reverse transcription-polymerase chain reaction. Clin Cancer Res. 1996 Oct;2(10):1757–1765. [PubMed] [Google Scholar]
  21. Van Roy N., Laureys G., Cheng N. C., Willem P., Opdenakker G., Versteeg R., Speleman F. 1;17 translocations and other chromosome 17 rearrangements in human primary neuroblastoma tumors and cell lines. Genes Chromosomes Cancer. 1994 Jun;10(2):103–114. doi: 10.1002/gcc.2870100205. [DOI] [PubMed] [Google Scholar]
  22. Vandesompele J., Van Roy N., Van Gele M., Laureys G., Ambros P., Heimann P., Devalck C., Schuuring E., Brock P., Otten J. Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization. Genes Chromosomes Cancer. 1998 Oct;23(2):141–152. doi: 10.1002/(sici)1098-2264(199810)23:2<141::aid-gcc7>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  23. Yamada Y., Post S. R., Wang K., Tager H. S., Bell G. I., Seino S. Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):251–255. doi: 10.1073/pnas.89.1.251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Zhang C. Y., Yokogoshi Y., Yoshimoto K., Fujinaka Y., Matsumoto K., Saito S. Point mutation of the somatostatin receptor 2 gene in the human small cell lung cancer cell line COR-L103. Biochem Biophys Res Commun. 1995 May 25;210(3):805–815. doi: 10.1006/bbrc.1995.1730. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES